Calcimimetics in chronic kidney disease: evidence, opportunities and challenges.


Secondary hyperparathyroidism (SHPT) remains a highly prevalent and important complication in patients with chronic kidney disease (CKD). Indeed, SHPT may compromise bone health and contribute to the increased cardiovascular risks of these patients. Calcimimetic agents may help to control SHPT and to achieve the stringent mineral metabolism targets in… (More)
DOI: 10.1038/ki.2008.166


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.